

William Vickery joins Hybrigenics as Head of Corporate and Business Development

Paris, December 06, 2010 – Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has hired William Vickery as Head of Corporate and Business Development, a newly created position.

William worked for five years at ExonHit Therapeutics as Senior Director of Business Development. During this time, he negotiated multiple extensions to ExonHit Therapeutics' strategic partnership with Allergan, secured its participation in PharmaCog (the European Innovative Medicines Initiative consortium on Alzheimer's disease) and in-licensed a breast cancer diagnostic discovered by Gustave Roussy Institute.

Prior to joining ExonHit Therapeutics in 2006 and since 2003, William served as a Business Development Director of Roche Pharmaceuticals in the US. During his tenure, he was responsible for out-licensing and divestiture of Roche-developed assets. He led the Roche strategic alliance teams which established the alliances with Syrrx and Amira. From 2000 to 2003, he held various positions at Roche Pharmaceuticals headquarters in Switzerland, including business development responsibilities for CNS and metabolic diseases. He received an MBA from INSEAD and an engineering degree from HEI (Lille, France).

"I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases," said William Vickery, Hybrigenics' new Head of Corporate and Business Development.

"The addition of William Vickery to our management line-up is key to implementing our top priority strategy which is now focused on partnering inecalcitol for further clinical co-development in prostate cancer. His experience and track record both in Pharma and Biotech organizations will be extremely valuable," said Remi Delansorne, Hybrigenics' CEO.

About Hybrigenics

Hybrigenics SA (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics Services SAS is a fully-owned subsidiary of Hybrigenics SA, and the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life science, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS

Press Release

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.fr
